gefitinib has been researched along with licochalcone b in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (licochalcone b) | Trials (licochalcone b) | Recent Studies (post-2010) (licochalcone b) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 30 | 0 | 29 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chae, JI; Kim, E; Lee, MH; Oh, HN; Shim, JH; Yoon, G | 1 |
1 other study(ies) available for gefitinib and licochalcone b
| Article | Year |
|---|---|
Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycyrrhiza; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Reactive Oxygen Species | 2019 |